A phase I/II trial of cyberknife with radiotherapy and chemotherapy in postoperative residual grade IV glioma: radiation dose and safety

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100051541

Enrollment

Unknown

Registered

2021-09-26

Start date

2022-01-01

Completion date

Unknown

Last updated

2022-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glioma

Interventions

treatment group:Cyberknife 15Gy

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-80 years old; 2. Postoperative pathologically confirmed grade 4 glioma; 3. ECOG physical condition score: 0~1 points; 4. MRS+PWI after conventional postoperative IMRT indicates residual tumor; 5. Normal bone marrow function: white blood cell count > 4x10^9/L, hemoglobin > 90g/L and platelet count > 100x10^9/L; 6. Normal liver and kidney function: total bilirubin = 60 ml/min; 7. Patients must be informed of the basic content of this study and sign the informed consent; 8. Patients of childbearing age must take appropriate birth control measures (such as oral contraceptives).

Exclusion criteria

Exclusion criteria: 1. Received head radiation therapy in the past; 2. Contraindications to CyberKnife treatment; 3. CT or MRI scanning is contraindicated; 4. Coagulation disorders; 5. With other serious diseases, it may bring greater risks or affect the compliance of the test.

Design outcomes

Primary

Measure	Time frame
dose limiting toxicity;maximum tolerated dose;	—

Countries

China

Contacts

Public ContactQiao Qiao

the First Hospital of China Medical University

braveheart8063@outlook.com+86 13889368446

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026